Neurocrine [NBIX] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

Neurocrine Biosciences Inc.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Neurocrine Biosciences Inc. wins in 13 metrics, Haleon Plc - ADR wins in 7 metrics, with 0 ties. Neurocrine Biosciences Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Neurocrine Biosciences Inc. Haleon Plc - ADR Better
P/E Ratio (TTM) 27.88 18.72 Haleon Plc - ADR
Price-to-Book Ratio 4.01 1.88 Haleon Plc - ADR
Debt-to-Equity Ratio 14.49 52.37 Neurocrine Biosciences Inc.
PEG Ratio 0.56 15.42 Neurocrine Biosciences Inc.
EV/EBITDA 18.09 33.08 Neurocrine Biosciences Inc.
Profit Margin (TTM) 16.73% 15.11% Neurocrine Biosciences Inc.
Operating Margin (TTM) 28.21% 23.17% Neurocrine Biosciences Inc.
EBITDA Margin (TTM) 28.21% 23.17% Neurocrine Biosciences Inc.
Return on Equity 16.38% 10.27% Neurocrine Biosciences Inc.
Return on Assets (TTM) 9.53% 4.67% Neurocrine Biosciences Inc.
Free Cash Flow (TTM) $748.70M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return 28.43% -16.01% Neurocrine Biosciences Inc.
Price-to-Sales Ratio (TTM) 4.58 3.78 Haleon Plc - ADR
Enterprise Value $12.06B $122.54B Haleon Plc - ADR
EV/Revenue Ratio 4.22 8.23 Neurocrine Biosciences Inc.
Gross Profit Margin (TTM) 97.82% 55.38% Neurocrine Biosciences Inc.
Revenue per Share (TTM) $29 $2 Neurocrine Biosciences Inc.
Earnings per Share (Diluted) $4.67 $0.50 Neurocrine Biosciences Inc.
Beta (Stock Volatility) 0.35 0.33 Haleon Plc - ADR
Short % of Float 5.90% 0.43% Haleon Plc - ADR

Neurocrine Biosciences Inc. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

NBIX
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Neurocrine Biosciences Inc.-0.16%-2.21%0.69%22.84%3.54%13.45%
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Neurocrine Biosciences Inc.28.43%63.69%58.93%261.12%2,094.51%952.44%
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%

Performance & Financial Health Analysis: Neurocrine Biosciences Inc. vs Haleon Plc - ADR

MetricNBIXHLN
Market Information
Market Cap i$13.09B$42.40B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i1,084,1346,594,249
90 Day Avg. Volume i1,073,0657,985,230
Last Close$159.51$9.07
52 Week Range$122.14 - $169.57$8.65 - $11.28
% from 52W High-5.93%-19.59%
All-Time High$169.57 (Jun 04, 2026)$11.42 (Jun 02, 2025)
% from All-Time High-5.93%-20.58%
Growth Metrics
Quarterly Revenue Growth0.28%0.01%
Quarterly Earnings Growth0.49%0.86%
Financial Health
Profit Margin (TTM) i0.17%0.15%
Operating Margin (TTM) i0.28%0.23%
Return on Equity (TTM) i0.16%0.10%
Debt to Equity (MRQ) i14.4952.37
Cash & Liquidity
Book Value per Share (MRQ)$32.50$4.99
Cash per Share (MRQ)$14.75$0.15
Operating Cash Flow (TTM) i$782.70M$3.56B
Levered Free Cash Flow (TTM) i$397.81M$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: Neurocrine Biosciences Inc. vs Haleon Plc - ADR

MetricNBIX (Apr 24, 2026)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i27.8818.72
Forward P/E i14.6715.42
PEG Ratio i0.5615.42
Price to Sales (TTM) i4.583.78
Price to Book (MRQ) i4.011.88
Market Capitalization
Market Capitalization i$13.09B$42.40B
Enterprise Value i$12.06B$122.54B
Enterprise Value Metrics
Enterprise to Revenue i4.228.23
Enterprise to EBITDA i18.0933.08
Risk & Other Metrics
Beta i0.350.33
Book Value per Share (MRQ) i$32.50$4.99

Financial Statements Comparison: Neurocrine Biosciences Inc. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNBIX (2025)HLN (2025)
Revenue/Sales i2.86B11.03B
Cost of Goods Sold i52.10M3.95B
COGS % of Revenue i1.8%35.8%
Gross Profit i2.81B7.08B
Gross Margin i98.2%64.2%
Research & Development i1.02B316.00M
Operating Income (EBIT) i636.50M2.41B
Operating Margin i22.3%21.9%
EBITDA i688.00M2.81B
EBITDA Margin i24.1%25.5%
Pre-Tax Income i705.40M2.15B
Pre-Tax Income % of Revenue i24.7%19.5%
Income Tax i226.80M472.00M
Income Tax % of Revenue i7.9%4.3%
Net Income (Profit) i478.60M1.68B
Profit Margin i16.7%15.2%

Balance Sheet & Liquidity Metrics

MetricNBIX (2025)HLN (2025)
Cash & Equivalents i713.00M1.26B
Total Current Assets i2.52B4.55B
Total Current Assets % of Revenue i88.2%41.3%
Total Current Liabilities i743.40M4.93B
Total Current Liabilities % of Revenue i26.0%44.7%
Long-Term Debt i415.30M7.75B
Long-Term Debt % of Revenue i14.5%70.2%
Total Shareholders Equity i3.25B16.48B
Retained Earnings i447.70M27.85B
Retained Earnings % of Revenue i15.7%252.5%
Property, Plant & Equipment i578.70M1.00M

Cash Flow Statement Comparison

MetricNBIX (2025)HLN (2025)
Operating Cash Flow i617.80M2.19B
Operating Cash Flow % of Revenue i21.6%19.8%
Capital Expenditures iN/A-322.00M
Free Cash Flow i748.70M2.22B
FCF Margin i26.2%20.1%
Debt Repayment i0-1.35B
Common Stock Repurchase i-167.70M-654.00M

Short Interest & Institutional Ownership Analysis

MetricNBIXHLN
Shares Short i4.56M19.28M
Short Ratio i4.772.14
Short % of Float i5.90%0.43%
Shares Outstanding i100.10M8.91B
Float Shares i99.07M8.86B
% Held by Insiders i1.10%0.01%
% Held by Institutions i101.35%12.74%
% Held by Public i-2.45%87.25%

Dividend Analysis & Yield Comparison: Neurocrine Biosciences Inc. vs Haleon Plc - ADR

MetricNBIXHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025